Revelation Biosciences, Inc. REVB
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- +9.37%
- 1 year
- +2.94%
5D -0.26 (-6.09%)
- Market cap
- 1.99M
- EPS (ttm)
- -99.96
- Shares out
- 8.36M
- Forward P/E
- -0.13
- YTD return
- +9.37%
- 1-year return
- +2.94%
- 50-day average
- 0.7149
- Volume
- 9.80K
- Avg volume
- 12.36K
- Open
- 3.71
- Previous close
- 3.69
- Day's range
- 3.50 – 3.80
- 52-week range
- 3.08 – 40.60
- Price target
- 12.75 (+264.3%)
Key statistics
- 200-day average
- 1.49
- Enterprise value
- -5.27M
- Price / book
- 0.49
- Free cash flow
- -6.49M
- Total cash
- 6.54M
- Return on equity
- -270.02%
- Short % of float
- 2.93%
Fundamental scorecard
4 of 25 checks passed on REVB’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -2.84 | -0.84 | +2.00 | +70.42% |
| Aug 9, 2024 | Jun 1, 2024 | -1.81 | -1.54 | +0.27 | +14.92% |
| Aug 9, 2024 | Jun 1, 2024 | -1.81 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -5.39 | -2.46 | +2.93 | +54.36% |
| May 10, 2024 | Mar 1, 2024 | -5.39 | — | — | — |
| Mar 22, 2024 | Dec 1, 2023 | -10.94 | -8.33 | +2.61 | +23.86% |
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revbiosciences.com
News
Revelation Biosciences Plans Accelerate Development Of Its Therapeutic Candidate Gemini; New Streamlined Phase 2a Study In Acute Kidney Injury To Deliver Topline Data In 2027 At Nearly 90% Lower Costs
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives Revelation Biosciences Q3 EPS $(5.92) Beats $(6.16) Estimate
Your note
Sign in to keep a note on REVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| TIDMARSH GEORGE F | Director | Sale | Dec 7, 2023 | 42,096 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 0.51% | 42,226 | 12.77K | Sep 29, 2024 |
| UBS Group AG | 0.49% | 40,945 | 12.38K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.16% | 13,258 | 4.01K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 2,539 | 767 | Sep 29, 2024 |
| Pom Investment Strategies, LLC | 0.00% | 1 | 0 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 29 | 8 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.10% | 8,022 | 2.42K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 2,942 | 889 | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 201 | 60 | Sep 29, 2024 |
